Todos Medical Ltd (OP: TOMDF )
0.0010 UNCHANGED Streaming Delayed Price Updated: 3:59 PM EDT, Jun 6, 2023 Add to My Watchlist
Headline News about Todos Medical Ltd
Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer's Paxlovid Approval, Tollovir™ Phase 2 & COVID Testing
December 23, 2021
CEO Gerald Commissiong is also scheduled to appear on BNC at 1:50PM EST to discuss the authorization of Pfizer’s COVID antiviral drug & Tollovir™ Phase 2 for...
Todos Medical Announces New cPass Neutralizing Antibody Testing Reference Lab Agreement for CLIA/CAP Lab Provista with Physician Group in 40 States
December 22, 2021
Provista completed validation for fingerprick At-Home sample collection of blood for the cPass neutralizing antibody test New York, NY, and Tel Aviv, ISRAEL...
Todos Medical to Host Key Opinion Leader Webinar Entitled Tollovir™: a Potential Treatment for Covid-19
December 16, 2021
Webinar to be held on December 22nd @ 12pm EST NLC Pharma and Todos agree to extend closing date for formation of 3CL Sciences to December 31, 2021 while the companies...
Todos Medical Enters 90-Day Extension of Agreement with Convertible Note Holders on Moratorium on Conversions of Convertible Notes
December 13, 2021
New York, NY, Alpharetta, GA and Tel Aviv, ISRAEL – December 13, 2021 - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company...
Todos Medical Interview and Presentation on Benzinga's All Access Conference Live December 14th at 10:20 AM EST
December 10, 2021
New York, NY, and Tel Aviv, ISRAEL – December 10, 2021 - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today...
Todos Medical Announces 2 New COVID-19 PCR Testing Reference Lab Agreements for CLIA/CAP Lab Provista Diagnostics
December 07, 2021
Combined testing from two contracts averages 1000 PCR samples per day Testing potential for the two contracts could ramp up to 5000 PCR samples per day New York, NY, Alpharetta...
Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation
December 02, 2021
Dr. Jules Mitchel now leading preparation for data lock and statistical analysis Business update call Today at 4:30PM EST New York, NY, and Tel Aviv, ISRAEL – December 2,...
Todos Medical Confirms SARS-CoV-2 PCR Test Kits Used at CLIA/CAP Lab Provista Diagnostics Detect Omicron Variant
November 30, 2021
Provista to also utilize e Osang’s High-Capacity Reflex Variant PCR Detection Kit that has been confirmed to identify the Omicron variant New York, NY, and Tel Aviv, ISRAEL...
Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma
November 30, 2021
Company to form majority owned subsidiary, 3CL Sciences, an entity focused on the development of variant-agnostic COVID-19 antivirals such as Tollovir that utilize the 3CL...
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Todos Medical Receives Purchase Order for 50,000 Bottles of Tollovid Daily™ from Its European Distribution Partner T-Cell Protect Hellas S.A for Initial Market Launch in Greece
November 22, 2021
T-Cell Protect is also evaluating expected demand for maximum strength Tollovid® New York, NY, and Tel Aviv, ISRAEL – November 22, 2021 - Todos Medical, Ltd. (OTCQB:...
Todos Medical Announces Completion of Enrollment for COVID-19 Oral Antiviral 3CLPro (Mpro) Inhibitor Tollovir® Phase 2 Clinical Trial Interim Analysis in Severe and Critical Hospitalized Patients
November 19, 2021
Enrollment now paused in the randomized, double blind, placebo controlled clinical trial in severe and critical hospitalized COVID-19 patients to complete interim analysis Data...
Todos Medical Announces Tollovid® Products Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. Covering 30 Countries in Europe
November 18, 2021
The agreement calls for a minimum of 500,000 bottles in sales over 18 months T-Cell Protect to invest 1 million euros in Todos to support development of Tollovir, the Company...
Todos Medical Announces Addition of Semi-Quantitative Titer Claims to the Emergency Use Authorization for the cPass Neutralizing Antibody Test
November 18, 2021
Reauthorization of EUA expands beyond initial qualitative detection claim CEO to appear on Cheddar News at 6:10pm tonight, November 17th, 2021 New York, NY, and Tel Aviv, ISRAEL...
Todos Medical's Provista Laboratory to Boost Top Line through New Atlanta-based Reference Lab Agreement for COVID PCR, cPass Neutralizing Antibody & Respiratory Pathogen Panel Tests
November 18, 2021
New York, NY, and Tel Aviv, ISRAEL – November 16, 2021 - Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related...
Todos Medical Says It Wants to Outfox COVID-19 & Cancer Along With Rivals Pfizer & Merck With New Theranostic Approach
November 05, 2021
Photo by Artem Podrez from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Molnupiravir? Not So Fast. What About Tollovir? — Here's Why You Should Know What That Means
October 12, 2021
Photo by Martin Sanchez on Unsplash Merck (NYSE: MRK) announced last Friday impressive results from its COVID-19 antiviral, molnupiravir. As vaccines are requiring a third booster...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following